Genome & Company Joins Eli Lilly TuneLab Platform
The South Korean biotech firm enters the Lilly TuneLab drug development platform to advance therapeutic research.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you believe artificial intelligence will significantly accelerate the discovery of life-saving drugs?
Genome & Company has joined the Eli Lilly drug development platform known as Lilly TuneLab. This partnership utilizes the TuneLab ecosystem to optimize the development potential of new drug candidates.
Why it matters
The collaboration is designed to leverage artificial intelligence to reduce the time and costs associated with bringing new pharmaceutical products to market. By integrating advanced platforms, the companies aim to accelerate the overall drug development lifecycle.
Genome & Company uses its proprietary GenoCL platform to discover antibody therapeutics and small-molecule compounds. Eli Lilly provides AI analysis trained on historical drug efficacy and safety data to predict the viability of these selections.
The players
Genome & Company
A biotechnology firm that specializes in the discovery of antibody therapeutics and small-molecule compounds through its GenoCL platform.
Eli Lilly
A global pharmaceutical company that maintains the Lilly Catalyze360 open innovation program and the AI-driven TuneLab development platform.
The details
The partnership integrates Genome & Company into the broader Lilly Catalyze360 open innovation program. Through this initiative, the firm plans to accelerate its technology transfer strategy while utilizing AI-driven insights to refine candidate substances.
Timeline
October 26, 2026: Announcement of Genome & Company joining the TuneLab platform.
The Tech Race
The partnership follows the strategic framework established by the Lilly Catalyze360 open innovation program, which provides a defined pipeline for external biotech firms to integrate their research with corporate AI resources. This reflects a broader industry shift where pharmaceutical giants prioritize AI-integrated platforms to replace manual drug candidate screening processes.
This development streamlines the R&D process, potentially accelerating the timeline for new antibody and small-molecule treatments to reach clinical trials. Over the long term, these efficiency gains could influence the availability and cost of novel medical therapies.
The takeaway
Artificial intelligence integration in drug development is becoming a standardized method for pharmaceutical companies to manage rising research costs. Biotech firms can benefit by aligning their proprietary discovery platforms with large-scale corporate data infrastructures.
Further reading
Explore ongoing advancements in medical innovation on our Biotech section page.
Live Poll
Do you believe artificial intelligence will significantly accelerate the discovery of life-saving drugs?
